Literature DB >> 22171207

Psychosis in the context of sodium oxybate therapy.

Jody Langford1, William L Gross.   

Abstract

Sodium oxybate (brand name Xyrem) is a sodium salt of gamma-hydroxybutyric acid (GHB), an endogenous CNS depressant, which is an effective treatment of narcolepsy. As a drug of abuse, GHB produces severe psychiatric side effects and withdrawal. However, there are no reports of these effects when using clinically recommended doses. This paper presents a case of a patient who developed altered mental status while taking the recommended dose of sodium oxybate and subsequently became psychotic upon abrupt discontinuation of the medication. It is important for prescribers of sodium oxybate to be aware of the possibility of significant psychiatric side effects of this medication, as well as withdrawal symptoms, even at clinical doses.

Entities:  

Keywords:  Sodium oxybate; narcolepsy; psychoses - substance-induced; substance withdrawal syndrome

Mesh:

Substances:

Year:  2011        PMID: 22171207      PMCID: PMC3227714          DOI: 10.5664/jcsm.1478

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  8 in total

1.  Suicidal ideation secondary to sodium oxybate.

Authors:  Juan Jose Ortega-Albás; Roberto López-Bernabé; Angel Luis Serrano García; Jose Ramón Díaz Gómez
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

Review 2.  Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion.

Authors:  Y Grace Wang; Todd J Swick; Lawrence P Carter; Michael J Thorpy; Neal L Benowitz
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

3.  Rapid occurrence of depression following addition of sodium oxybate to modafinil.

Authors:  Andrea O Rossetti; Raphaël C Heinzer; Mehdi Tafti; Thierry Buclin
Journal:  Sleep Med       Date:  2010-02-04       Impact factor: 3.492

Review 4.  Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy.

Authors:  Richard T Owen
Journal:  Drugs Today (Barc)       Date:  2008-03       Impact factor: 2.245

5.  Three deaths associated with use of Xyrem.

Authors:  Deborah L Zvosec; Stephen W Smith; Brad J Hall
Journal:  Sleep Med       Date:  2009-03-09       Impact factor: 3.492

Review 6.  Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review.

Authors:  Michael McDonough; Noel Kennedy; Anthony Glasper; Jenny Bearn
Journal:  Drug Alcohol Depend       Date:  2004-07-15       Impact factor: 4.492

7.  Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study.

Authors:  Judith C Barker; Shana L Harris; Jo E Dyer
Journal:  J Psychoactive Drugs       Date:  2007-06

8.  Gamma hydroxybutyrate: an ethnographic study of recreational use and abuse.

Authors:  Steven J Lee; Petros Levounis
Journal:  J Psychoactive Drugs       Date:  2008-09
  8 in total
  5 in total

Review 1.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

Review 2.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

3.  GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Tsui-Ming Chen; Andrew K Leung; Jonathan P Wisor; Akihiro Yamanaka; Thomas S Kilduff
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

Review 4.  Pediatric Narcolepsy-A Practical Review.

Authors:  I-Hang Chung; Wei-Chih Chin; Yu-Shu Huang; Chih-Huan Wang
Journal:  Children (Basel)       Date:  2022-06-29

5.  Psychosis in patients with narcolepsy as an adverse effect of sodium oxybate.

Authors:  Tomi Sarkanen; Valter Niemelä; Anne-Marie Landtblom; Markku Partinen
Journal:  Front Neurol       Date:  2014-08-20       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.